APO Research
Talk to an analyst

APO RESEARCH · REPORT

Hepatic Encephalopathy (HE) Therapeutics

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Hepatic Encephalopathy (HE) Therapeutics Market Outlook and Growth Opportunities 2026

22 December 2025190 pages

Choose your research edition.

Industry ResearchHepatic Encephalopathy (HE) Therapeutics Industry Research Report 2026106 pages · $2,950 USDIndustry Growth & TrendsGlobal Hepatic Encephalopathy (HE) Therapeutics Industry Growth and Trends Forecast to 203261 pages · $3,450 USDMarket StructureGlobal Hepatic Encephalopathy (HE) Therapeutics Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032179 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Hepatic Encephalopathy (HE) Therapeutics Market Outlook and Growth Opportunities 2026190 pages · $4,250 USDMarket Analysis & ForecastGlobal Hepatic Encephalopathy (HE) Therapeutics Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Hepatic Encephalopathy (HE) Therapeutics market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Hepatic Encephalopathy (HE) Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Hepatic Encephalopathy (HE) Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Hepatic Encephalopathy (HE) Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Hepatic Encephalopathy (HE) Therapeutics market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Hepatic Encephalopathy (HE) Therapeutics market include ASKA Pharmaceutical, COSMO PHARMACEUTICALS, Mallinckrodt and Valeant, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Hepatic Encephalopathy (HE) Therapeutics market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Hepatic Encephalopathy (HE) Therapeutics and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Hepatic Encephalopathy (HE) Therapeutics revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Hepatic Encephalopathy (HE) Therapeutics market.

Hepatic Encephalopathy (HE) Therapeutics Segment by Company

ASKA Pharmaceutical

COSMO PHARMACEUTICALS

Mallinckrodt

Valeant

Hepatic Encephalopathy (HE) Therapeutics Segment by Type

Probiotics

Neomycin

Lactulose

Thiamine

Rifaximin

Hepatic Encephalopathy (HE) Therapeutics Segment by Application

Acute Liver Failure

Liver Cirrhosis

Hepatic Encephalopathy (HE) Therapeutics Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Hepatic Encephalopathy (HE) Therapeutics status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Hepatic Encephalopathy (HE) Therapeutics key companies, revenue, market share, and recent developments.

3. To split the Hepatic Encephalopathy (HE) Therapeutics breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Hepatic Encephalopathy (HE) Therapeutics market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Hepatic Encephalopathy (HE) Therapeutics significant trends, drivers, influence factors in global and regions.

6. To analyze Hepatic Encephalopathy (HE) Therapeutics competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Hepatic Encephalopathy (HE) Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Hepatic Encephalopathy (HE) Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Hepatic Encephalopathy (HE) Therapeutics.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Hepatic Encephalopathy (HE) Therapeutics industry.

Chapter 3: Detailed analysis of Hepatic Encephalopathy (HE) Therapeutics company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Hepatic Encephalopathy (HE) Therapeutics in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Hepatic Encephalopathy (HE) Therapeutics in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Hepatic Encephalopathy (HE) Therapeutics Industry Trends Table 2. Hepatic Encephalopathy (HE) Therapeutics Industry Drivers Table 3. Hepatic Encephalopathy (HE) Therapeutics Industry Opportunities and Challenges Table 4. Hepatic Encephalopathy (HE) Therapeutics Industry Restraints Table 5. Global Hepatic Encephalopathy (HE) Therapeutics Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Hepatic Encephalopathy (HE) Therapeutics Revenue Share by Company (2021-2026) Table 7. Global Hepatic Encephalopathy (HE) Therapeutics Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Hepatic Encephalopathy (HE) Therapeutics Key Company Manufacturing Base & Headquarters Table 9. Global Hepatic Encephalopathy (HE) Therapeutics Company, Product Type & Application Table 10. Global Hepatic Encephalopathy (HE) Therapeutics Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Hepatic Encephalopathy (HE) Therapeutics by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Probiotics Table 15. Significant Companies of Neomycin Table 16. Significant Companies of Lactulose Table 17. Significant Companies of Thiamine Table 18. Significant Companies of Rifaximin Table 19. Global Hepatic Encephalopathy (HE) Therapeutics Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 20. Global Hepatic Encephalopathy (HE) Therapeutics Sales Value by Type (2021-2026) & (US$ Million) Table 21. Global Hepatic Encephalopathy (HE) Therapeutics Sales Value by Type (2027-2032) & (US$ Million) Table 22. Global Hepatic Encephalopathy (HE) Therapeutics Sales Value Share by Type (2021-2026) Table 23. Global Hepatic Encephalopathy (HE) Therapeutics Sales Value Share by Type (2027-2032) Table 24. Significant Companies of Acute Liver Failure Table 25. Significant Companies of Liver Cirrhosis Table 26. Global Hepatic Encephalopathy (HE) Therapeutics Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Hepatic Encephalopathy (HE) Therapeutics Sales Value by Application (2021-2026) & (US$ Million) Table 28. Global Hepatic Encephalopathy (HE) Therapeutics Sales Value by Application (2027-2032) & (US$ Million) Table 29. Global Hepatic Encephalopathy (HE) Therapeutics Sales Value Share by Application (2021-2026) Table 30. Global Hepatic Encephalopathy (HE) Therapeutics Sales Value Share by Application (2027-2032) Table 31. Global Hepatic Encephalopathy (HE) Therapeutics Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Hepatic Encephalopathy (HE) Therapeutics Sales Value by Region (2021-2026) & (US$ Million) Table 33. Global Hepatic Encephalopathy (HE) Therapeutics Sales Value Share by Region (2021-2026) Table 34. Global Hepatic Encephalopathy (HE) Therapeutics Sales Value by Region (2027-2032) & (US$ Million) Table 35. Global Hepatic Encephalopathy (HE) Therapeutics Sales Value Share by Region (2027-2032) Table 36. Global Hepatic Encephalopathy (HE) Therapeutics Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Hepatic Encephalopathy (HE) Therapeutics Sales Value by Country (2021-2026) & (US$ Million) Table 38. Global Hepatic Encephalopathy (HE) Therapeutics Sales Value Market Share by Country (2021-2026) Table 39. Global Hepatic Encephalopathy (HE) Therapeutics Sales Value by Country (2027-2032) & (US$ Million) Table 40. Global Hepatic Encephalopathy (HE) Therapeutics Sales Value Market Share by Country (2027-2032) Table 41. ASKA Pharmaceutical Company Information Table 42. ASKA Pharmaceutical Business Overview Table 43. ASKA Pharmaceutical Hepatic Encephalopathy (HE) Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 44. ASKA Pharmaceutical Hepatic Encephalopathy (HE) Therapeutics Product Portfolio Table 45. ASKA Pharmaceutical Recent Development Table 46. COSMO PHARMACEUTICALS Company Information Table 47. COSMO PHARMACEUTICALS Business Overview Table 48. COSMO PHARMACEUTICALS Hepatic Encephalopathy (HE) Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 49. COSMO PHARMACEUTICALS Hepatic Encephalopathy (HE) Therapeutics Product Portfolio Table 50. COSMO PHARMACEUTICALS Recent Development Table 51. Mallinckrodt Company Information Table 52. Mallinckrodt Business Overview Table 53. Mallinckrodt Hepatic Encephalopathy (HE) Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 54. Mallinckrodt Hepatic Encephalopathy (HE) Therapeutics Product Portfolio Table 55. Mallinckrodt Recent Development Table 56. Valeant Company Information Table 57. Valeant Business Overview Table 58. Valeant Hepatic Encephalopathy (HE) Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 59. Valeant Hepatic Encephalopathy (HE) Therapeutics Product Portfolio Table 60. Valeant Recent Development Table 61. Research Programs/Design for This Report Table 62. Authors List of This Report Table 63. Secondary Sources Table 64. Primary Sources List of Figures Figure 1. Hepatic Encephalopathy (HE) Therapeutics Product Image Figure 2. Global Hepatic Encephalopathy (HE) Therapeutics Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Hepatic Encephalopathy (HE) Therapeutics Market Size (2021-2032) & (US$ Million) Figure 4. Global Hepatic Encephalopathy (HE) Therapeutics Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Probiotics Image Figure 8. Neomycin Image Figure 9. Lactulose Image Figure 10. Thiamine Image Figure 11. Rifaximin Image Figure 12. Global Hepatic Encephalopathy (HE) Therapeutics Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 13. Global Hepatic Encephalopathy (HE) Therapeutics Sales Value Share 2021 VS 2025 VS 2032 Figure 14. Global Hepatic Encephalopathy (HE) Therapeutics Sales Value Share by Type (2021-2032) Figure 15. Acute Liver Failure Image Figure 16. Liver Cirrhosis Image Figure 17. Global Hepatic Encephalopathy (HE) Therapeutics Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Hepatic Encephalopathy (HE) Therapeutics Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global Hepatic Encephalopathy (HE) Therapeutics Sales Value Share by Application (2021-2032) Figure 20. Global Hepatic Encephalopathy (HE) Therapeutics Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 21. Global Hepatic Encephalopathy (HE) Therapeutics Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 22. North America Hepatic Encephalopathy (HE) Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 23. North America Hepatic Encephalopathy (HE) Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Europe Hepatic Encephalopathy (HE) Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 25. Europe Hepatic Encephalopathy (HE) Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 26. Asia-Pacific Hepatic Encephalopathy (HE) Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 27. Asia-Pacific Hepatic Encephalopathy (HE) Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 28. South America Hepatic Encephalopathy (HE) Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 29. South America Hepatic Encephalopathy (HE) Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 30. Middle East & Africa Hepatic Encephalopathy (HE) Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 31. Middle East & Africa Hepatic Encephalopathy (HE) Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 32. USA Hepatic Encephalopathy (HE) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 33. USA Hepatic Encephalopathy (HE) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 34. USA Hepatic Encephalopathy (HE) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 35. Canada Hepatic Encephalopathy (HE) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. Canada Hepatic Encephalopathy (HE) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. Canada Hepatic Encephalopathy (HE) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Mexico Hepatic Encephalopathy (HE) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Mexico Hepatic Encephalopathy (HE) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Mexico Hepatic Encephalopathy (HE) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. Germany Hepatic Encephalopathy (HE) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. Germany Hepatic Encephalopathy (HE) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. Germany Hepatic Encephalopathy (HE) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. France Hepatic Encephalopathy (HE) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. France Hepatic Encephalopathy (HE) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. France Hepatic Encephalopathy (HE) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. U.K. Hepatic Encephalopathy (HE) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. U.K. Hepatic Encephalopathy (HE) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. U.K. Hepatic Encephalopathy (HE) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Italy Hepatic Encephalopathy (HE) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Italy Hepatic Encephalopathy (HE) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Italy Hepatic Encephalopathy (HE) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Spain Hepatic Encephalopathy (HE) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Spain Hepatic Encephalopathy (HE) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Spain Hepatic Encephalopathy (HE) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Russia Hepatic Encephalopathy (HE) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Russia Hepatic Encephalopathy (HE) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Russia Hepatic Encephalopathy (HE) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Netherlands Hepatic Encephalopathy (HE) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Netherlands Hepatic Encephalopathy (HE) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Netherlands Hepatic Encephalopathy (HE) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Nordic Countries Hepatic Encephalopathy (HE) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Nordic Countries Hepatic Encephalopathy (HE) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Nordic Countries Hepatic Encephalopathy (HE) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. China Hepatic Encephalopathy (HE) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. China Hepatic Encephalopathy (HE) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. China Hepatic Encephalopathy (HE) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Japan Hepatic Encephalopathy (HE) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Japan Hepatic Encephalopathy (HE) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Japan Hepatic Encephalopathy (HE) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. South Korea Hepatic Encephalopathy (HE) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. South Korea Hepatic Encephalopathy (HE) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. South Korea Hepatic Encephalopathy (HE) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. India Hepatic Encephalopathy (HE) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. India Hepatic Encephalopathy (HE) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. India Hepatic Encephalopathy (HE) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Australia Hepatic Encephalopathy (HE) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Australia Hepatic Encephalopathy (HE) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Australia Hepatic Encephalopathy (HE) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Southeast Asia Hepatic Encephalopathy (HE) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Southeast Asia Hepatic Encephalopathy (HE) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Southeast Asia Hepatic Encephalopathy (HE) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Brazil Hepatic Encephalopathy (HE) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Brazil Hepatic Encephalopathy (HE) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Brazil Hepatic Encephalopathy (HE) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Argentina Hepatic Encephalopathy (HE) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Argentina Hepatic Encephalopathy (HE) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Argentina Hepatic Encephalopathy (HE) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Chile Hepatic Encephalopathy (HE) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Chile Hepatic Encephalopathy (HE) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Chile Hepatic Encephalopathy (HE) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Colombia Hepatic Encephalopathy (HE) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Colombia Hepatic Encephalopathy (HE) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Colombia Hepatic Encephalopathy (HE) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Peru Hepatic Encephalopathy (HE) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Peru Hepatic Encephalopathy (HE) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Peru Hepatic Encephalopathy (HE) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Hepatic Encephalopathy (HE) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Saudi Arabia Hepatic Encephalopathy (HE) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Saudi Arabia Hepatic Encephalopathy (HE) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Israel Hepatic Encephalopathy (HE) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Israel Hepatic Encephalopathy (HE) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Israel Hepatic Encephalopathy (HE) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. UAE Hepatic Encephalopathy (HE) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. UAE Hepatic Encephalopathy (HE) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. UAE Hepatic Encephalopathy (HE) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Turkey Hepatic Encephalopathy (HE) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Turkey Hepatic Encephalopathy (HE) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Turkey Hepatic Encephalopathy (HE) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Iran Hepatic Encephalopathy (HE) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Iran Hepatic Encephalopathy (HE) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Iran Hepatic Encephalopathy (HE) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Egypt Hepatic Encephalopathy (HE) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Egypt Hepatic Encephalopathy (HE) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Egypt Hepatic Encephalopathy (HE) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Years Considered Figure 117. Research Process Figure 118. Key Executives Interviewed

Scope & coverage.

Types
  • Probiotics
  • Neomycin
  • Lactulose
  • Thiamine
  • Rifaximin
Applications
  • Acute Liver Failure
  • Liver Cirrhosis
Companies covered
  • ASKA Pharmaceutical
  • COSMO PHARMACEUTICALS
  • Mallinckrodt
  • Valeant

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Hepatic Encephalopathy (HE) Therapeutics Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Hepatic Encephalopathy (HE) Therapeutics Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Hepatic Encephalopathy (HE) Therapeutics Market Dynamics
  1. 2.1 Hepatic Encephalopathy (HE) Therapeutics Industry Trends
  2. 2.2 Hepatic Encephalopathy (HE) Therapeutics Industry Drivers
  3. 2.3 Hepatic Encephalopathy (HE) Therapeutics Industry Opportunities and Challenges
  4. 2.4 Hepatic Encephalopathy (HE) Therapeutics Industry Restraints
3 Hepatic Encephalopathy (HE) Therapeutics Market by Company
  1. 3.1 Global Hepatic Encephalopathy (HE) Therapeutics Company Revenue Ranking in 2025
  2. 3.2 Global Hepatic Encephalopathy (HE) Therapeutics Revenue by Company (2021-2026)
  3. 3.3 Global Hepatic Encephalopathy (HE) Therapeutics Company Ranking (2024-2026)
  4. 3.4 Global Hepatic Encephalopathy (HE) Therapeutics Company Manufacturing Base and Headquarters
  5. 3.5 Global Hepatic Encephalopathy (HE) Therapeutics Company Product Type and Application
  6. 3.6 Global Hepatic Encephalopathy (HE) Therapeutics Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Hepatic Encephalopathy (HE) Therapeutics Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Hepatic Encephalopathy (HE) Therapeutics Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Hepatic Encephalopathy (HE) Therapeutics Market by Type
  1. 4.1 Hepatic Encephalopathy (HE) Therapeutics Type Introduction
  2. 4.1.1 Probiotics
  3. 4.1.2 Neomycin
  4. 4.1.3 Lactulose
  5. 4.1.4 Thiamine
  6. 4.1.5 Rifaximin
  7. 4.2 Global Hepatic Encephalopathy (HE) Therapeutics Sales Value by Type
  8. 4.2.1 Global Hepatic Encephalopathy (HE) Therapeutics Sales Value by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Hepatic Encephalopathy (HE) Therapeutics Sales Value by Type (2021-2032)
  10. 4.2.3 Global Hepatic Encephalopathy (HE) Therapeutics Sales Value Share by Type (2021-2032)
5 Hepatic Encephalopathy (HE) Therapeutics Market by Application
  1. 5.1 Hepatic Encephalopathy (HE) Therapeutics Application Introduction
  2. 5.1.1 Acute Liver Failure
  3. 5.1.2 Liver Cirrhosis
  4. 5.2 Global Hepatic Encephalopathy (HE) Therapeutics Sales Value by Application
  5. 5.2.1 Global Hepatic Encephalopathy (HE) Therapeutics Sales Value by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Hepatic Encephalopathy (HE) Therapeutics Sales Value by Application (2021-2032)
  7. 5.2.3 Global Hepatic Encephalopathy (HE) Therapeutics Sales Value Share by Application (2021-2032)
6 Hepatic Encephalopathy (HE) Therapeutics Regional Value Analysis
  1. 6.1 Global Hepatic Encephalopathy (HE) Therapeutics Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Hepatic Encephalopathy (HE) Therapeutics Sales Value by Region (2021-2032)
  3. 6.2.1 Global Hepatic Encephalopathy (HE) Therapeutics Sales Value by Region: 2021-2026
  4. 6.2.2 Global Hepatic Encephalopathy (HE) Therapeutics Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Hepatic Encephalopathy (HE) Therapeutics Sales Value (2021-2032)
  7. 6.3.2 North America Hepatic Encephalopathy (HE) Therapeutics Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Hepatic Encephalopathy (HE) Therapeutics Sales Value (2021-2032)
  10. 6.4.2 Europe Hepatic Encephalopathy (HE) Therapeutics Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Hepatic Encephalopathy (HE) Therapeutics Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Hepatic Encephalopathy (HE) Therapeutics Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Hepatic Encephalopathy (HE) Therapeutics Sales Value (2021-2032)
  16. 6.6.2 South America Hepatic Encephalopathy (HE) Therapeutics Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Hepatic Encephalopathy (HE) Therapeutics Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Hepatic Encephalopathy (HE) Therapeutics Sales Value Share by Country, 2025 VS 2032
7 Hepatic Encephalopathy (HE) Therapeutics Country-level Value Analysis
  1. 7.1 Global Hepatic Encephalopathy (HE) Therapeutics Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Hepatic Encephalopathy (HE) Therapeutics Sales Value by Country (2021-2032)
  3. 7.2.1 Global Hepatic Encephalopathy (HE) Therapeutics Sales Value by Country (2021-2026)
  4. 7.2.2 Global Hepatic Encephalopathy (HE) Therapeutics Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Hepatic Encephalopathy (HE) Therapeutics Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Hepatic Encephalopathy (HE) Therapeutics Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Hepatic Encephalopathy (HE) Therapeutics Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Hepatic Encephalopathy (HE) Therapeutics Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Hepatic Encephalopathy (HE) Therapeutics Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Hepatic Encephalopathy (HE) Therapeutics Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Hepatic Encephalopathy (HE) Therapeutics Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Hepatic Encephalopathy (HE) Therapeutics Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Hepatic Encephalopathy (HE) Therapeutics Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Hepatic Encephalopathy (HE) Therapeutics Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Hepatic Encephalopathy (HE) Therapeutics Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Hepatic Encephalopathy (HE) Therapeutics Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Hepatic Encephalopathy (HE) Therapeutics Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Hepatic Encephalopathy (HE) Therapeutics Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Hepatic Encephalopathy (HE) Therapeutics Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Hepatic Encephalopathy (HE) Therapeutics Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Hepatic Encephalopathy (HE) Therapeutics Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Hepatic Encephalopathy (HE) Therapeutics Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Hepatic Encephalopathy (HE) Therapeutics Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Hepatic Encephalopathy (HE) Therapeutics Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Hepatic Encephalopathy (HE) Therapeutics Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Hepatic Encephalopathy (HE) Therapeutics Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Hepatic Encephalopathy (HE) Therapeutics Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Hepatic Encephalopathy (HE) Therapeutics Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Hepatic Encephalopathy (HE) Therapeutics Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Hepatic Encephalopathy (HE) Therapeutics Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Hepatic Encephalopathy (HE) Therapeutics Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Hepatic Encephalopathy (HE) Therapeutics Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Hepatic Encephalopathy (HE) Therapeutics Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Hepatic Encephalopathy (HE) Therapeutics Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Hepatic Encephalopathy (HE) Therapeutics Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Hepatic Encephalopathy (HE) Therapeutics Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Hepatic Encephalopathy (HE) Therapeutics Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Hepatic Encephalopathy (HE) Therapeutics Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Hepatic Encephalopathy (HE) Therapeutics Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Hepatic Encephalopathy (HE) Therapeutics Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Hepatic Encephalopathy (HE) Therapeutics Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Hepatic Encephalopathy (HE) Therapeutics Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Hepatic Encephalopathy (HE) Therapeutics Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Hepatic Encephalopathy (HE) Therapeutics Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Hepatic Encephalopathy (HE) Therapeutics Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Hepatic Encephalopathy (HE) Therapeutics Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Hepatic Encephalopathy (HE) Therapeutics Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Hepatic Encephalopathy (HE) Therapeutics Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Hepatic Encephalopathy (HE) Therapeutics Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Hepatic Encephalopathy (HE) Therapeutics Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Hepatic Encephalopathy (HE) Therapeutics Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Hepatic Encephalopathy (HE) Therapeutics Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Hepatic Encephalopathy (HE) Therapeutics Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Hepatic Encephalopathy (HE) Therapeutics Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Hepatic Encephalopathy (HE) Therapeutics Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Hepatic Encephalopathy (HE) Therapeutics Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Hepatic Encephalopathy (HE) Therapeutics Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Hepatic Encephalopathy (HE) Therapeutics Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Hepatic Encephalopathy (HE) Therapeutics Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Hepatic Encephalopathy (HE) Therapeutics Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Hepatic Encephalopathy (HE) Therapeutics Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Hepatic Encephalopathy (HE) Therapeutics Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Hepatic Encephalopathy (HE) Therapeutics Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Hepatic Encephalopathy (HE) Therapeutics Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Hepatic Encephalopathy (HE) Therapeutics Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Hepatic Encephalopathy (HE) Therapeutics Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Hepatic Encephalopathy (HE) Therapeutics Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Hepatic Encephalopathy (HE) Therapeutics Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Hepatic Encephalopathy (HE) Therapeutics Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Hepatic Encephalopathy (HE) Therapeutics Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Hepatic Encephalopathy (HE) Therapeutics Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Hepatic Encephalopathy (HE) Therapeutics Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Hepatic Encephalopathy (HE) Therapeutics Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Hepatic Encephalopathy (HE) Therapeutics Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Hepatic Encephalopathy (HE) Therapeutics Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Hepatic Encephalopathy (HE) Therapeutics Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Hepatic Encephalopathy (HE) Therapeutics Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Hepatic Encephalopathy (HE) Therapeutics Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Hepatic Encephalopathy (HE) Therapeutics Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Hepatic Encephalopathy (HE) Therapeutics Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Hepatic Encephalopathy (HE) Therapeutics Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Hepatic Encephalopathy (HE) Therapeutics Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Hepatic Encephalopathy (HE) Therapeutics Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Hepatic Encephalopathy (HE) Therapeutics Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Hepatic Encephalopathy (HE) Therapeutics Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Hepatic Encephalopathy (HE) Therapeutics Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Hepatic Encephalopathy (HE) Therapeutics Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Hepatic Encephalopathy (HE) Therapeutics Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 ASKA Pharmaceutical
  2. 8.1.1 ASKA Pharmaceutical Company Information
  3. 8.1.2 ASKA Pharmaceutical Business Overview
  4. 8.1.3 ASKA Pharmaceutical Hepatic Encephalopathy (HE) Therapeutics Revenue and Gross Margin (2021-2026)
  5. 8.1.4 ASKA Pharmaceutical Hepatic Encephalopathy (HE) Therapeutics Product Portfolio
  6. 8.1.5 ASKA Pharmaceutical Recent Developments
  7. 8.2 COSMO PHARMACEUTICALS
  8. 8.2.1 COSMO PHARMACEUTICALS Company Information
  9. 8.2.2 COSMO PHARMACEUTICALS Business Overview
  10. 8.2.3 COSMO PHARMACEUTICALS Hepatic Encephalopathy (HE) Therapeutics Revenue and Gross Margin (2021-2026)
  11. 8.2.4 COSMO PHARMACEUTICALS Hepatic Encephalopathy (HE) Therapeutics Product Portfolio
  12. 8.2.5 COSMO PHARMACEUTICALS Recent Developments
  13. 8.3 Mallinckrodt
  14. 8.3.1 Mallinckrodt Company Information
  15. 8.3.2 Mallinckrodt Business Overview
  16. 8.3.3 Mallinckrodt Hepatic Encephalopathy (HE) Therapeutics Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Mallinckrodt Hepatic Encephalopathy (HE) Therapeutics Product Portfolio
  18. 8.3.5 Mallinckrodt Recent Developments
  19. 8.4 Valeant
  20. 8.4.1 Valeant Company Information
  21. 8.4.2 Valeant Business Overview
  22. 8.4.3 Valeant Hepatic Encephalopathy (HE) Therapeutics Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Valeant Hepatic Encephalopathy (HE) Therapeutics Product Portfolio
  24. 8.4.5 Valeant Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst